Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers of medicine 2024-06, Vol.18 (3), p.565-569
Hauptverfasser:	Jia, Jia, Mao, Lili, Lin, Jing, Li, Wenyu, Yuan, Pei, Guo, Lei, Dai, Jie, Li, Caili, Bai, Xue, Li, Zhongwu, Chen, Yu, Guo, Jun, Ying, Jianming, Si, Lu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Female Humans Immunoconjugates - therapeutic use Letter to Frontiers of Medicine Male Medicine Medicine & Public Health Middle Aged Paget Disease, Extramammary - drug therapy Paget Disease, Extramammary - metabolism Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!